Artikel
Choroidal thickness under Anti-VEGF-therapy in exudative AMD
Suche in Medline nach
Autoren
-
Britta Heimes
- Münster, Germany
-
M. Ziegler
- Münster, Germany
-
B. Book
- Münster, Germany
-
D. Breiter
- Münster, Germany
-
A. Lommatzsch
- Münster, Germany
-
M. Gutfleisch
- Münster, Germany
-
M. Dietzel
- Münster, Germany
-
G. Spital
- Münster, Germany
-
M. Zeimer
- Münster, Germany
-
D. Pauleikhoff
- Münster, Germany
| Veröffentlicht: | 20. August 2013 |
|---|
Gliederung
Text
Background: Intravitreal anti-VEGF therapy represents the standard treatment of exudative AMD. So far the course of choroidal thickness during Anti-VEGF-therapy in AMD has not been reported extensively.
Methods: We observed 44 eyes with a mean follow up of 94 weeks under treatment with intravitreal ranibizumab (Lucentis®), who had at least a SD-OCT before treatment, and after 12, 24, and 36 weeks. In addition to fundoscopy, best corrected visual acuity (VA) and spectral domain OCT (Spectralis HRA III) were performed before and after treatment.
Results: After 12 weeks choroidal thickness decreased by 13 microns, which was not statistically significant. Despite subsequent pause of injections, the choroid thickness further decreased to a total decrease of 19 microns in week 24, which was statistically significant decrease compared to the choroidal thickness before treatment (p=0.0129, Bonferroni corrected). After that, the choroidal thickness increased again and showed no significant difference after 36 weeks compared to pre-treatment again.
Conclusions: Choroidal thickness decreased under anti-VEGF therapy in exudative AMD. Although the initial treatment was stopped in week 12, the lowest choroidal thickness has been measured in week 24 and increased subsequently.
